Dermatology

Yesintek Biosimilar Shows Comparable Efficacy, Lower Immunogenicity Than Stelara, Says Elena Wolff-Holz, MD

May 11th 2025

By Cameron Santoro

Elena Wolff-Holz, MD, discussed the approval and benefits of the ustekinumab biosimilar, Yesintek, emphasizing its comparable efficacy and safety to Stelara, and potential for increased patient access due to lower costs, and a possible lower immunogenicity profile.

Samsung Bioepis Report Signals Turning Point for US Biosimilars

May 1st 2025

By Skylar Jeremias

Article

A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.

Clinical Evidence Shows No Safety Gaps Between Biosimilar, Reference Adalimumab

April 26th 2025

By Deana Ferreri, PhD

Article

A plain language summary for patients explains there were no differences in safety outcomes between adalimumab-adbm and the originator in a pooled analysis of the VOLTAIRE clinical trials.

Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick

April 22nd 2025

By Skylar Jeremias

Article

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.

Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets

April 14th 2025

By Skylar Jeremias

Article

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.

Early Success of Adalimumab Biosimilars Featured at AMCP 2025

April 5th 2025

By Skylar Jeremias

Article

High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).

Adalimumab Biosimilars Show Similar Outcomes in Psoriasis After Nonmedical Switch

March 26th 2025

By Skylar Jeremias

Article

Switching between adalimumab products does not affect drug effectiveness or treatment duration in patients who have psoriasis, according to a Danish study.

Smart Tendering Policies Unlock Greater Biosimilar Savings

March 20th 2025

By Skylar Jeremias

Article

Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, while price-linked discounts and prescribing quotas have shown mixed or uncertain results.

Multiple Switches Between Adalimumab Biosimilar GP2017 and Humira for Psoriasis Maintain Biosimilarity

March 20th 2025

By Cameron Santoro

Article

Patients with moderate to severe plaque psoriasis who switched between the adalimumab biosimilar GP2017 and reference adalimumab did not impact immunogenicity, safety, or efficacy following up to 4 switches between both drugs.

Promising Results for Ustekinumab, Adalimumab Biosimilars Presented at AAD

March 18th 2025

By Skylar Jeremias

Article

Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved interchangeable with reference adalimumab, according to posters at the American Academy of Dermatology (AAD) annual meeting.